Handelsblatt : Alliance against Bayer: Hedge funds explore Allianz against the m

Alliance against Bayer: Hedge funds explore Allianz against the management

Activist investor Bluebell is stepping up criticism of Bayer and wants to get other dissatisfied funds behind it. The group is threatened with a new uprising by the shareholder

Activist investor Bluebell is stepping up criticism of Bayer and wants to get other dissatisfied funds behind it. The group is threatened with a new uprising by the shareholder

Düsseldorf, Frankfurt A possible alliance of influential investors challenges the Board of Management and the Supervisory Board of the Bayer Group in terms of strategy and management. According to financial circles, the activist investor Bluebell is gathering allies after joining the Leverkusen group in order to enforce his demands.

Since it became known that Bluebell was involved with Bayer , many investors had approached the activist, a person familiar with the matter told the Handelsblatt. These investors have "the same thoughts" and complained about the weak share price .

According to the information provided, Bluebell calls for a quick replacement of the CEO position with an external candidate. Bayer CEO Werner Baumann 's contract runs until April 2024. The investor is also demanding changes in the supervisory board and the splitting up of the group. A first step should be the spin-off of the business with non-prescription drugs around the Aspirin brand.